Unmasking the Future of Cancer Detection: 10 AI Startups Leading the Charge

LinkedIN post from: Lachezar Zanev

Welcome to the future of healthcare, where Artificial Intelligence (AI) and cutting-edge technology join hands to make a significant impact on patient outcomes. As we ride the wave of this digital health revolution, one of the most promising areas of application is cancer detection and treatment. Early detection of cancer is paramount to improving survival rates, and AI holds immense potential to accelerate this process.

Across the globe, a new breed of startups is harnessing the power of AI to pioneer innovative approaches for early cancer detection. These companies are leveraging advanced algorithms, deep

The novel scientific concept behind OpsisDx™, developed by Entopsis Inc., is outlined in a recently published peer-reviewed scientific manuscript in the Royal Society of Chemistry Analyst journal. In addition, OpsisDx™ was selected by the editors of the journal to be featured on the journal’s cover.

The manuscript, entitled ‘A colorimetric chemical tongue detects and distinguishes between
multiple analytes’, demonstrates how photoinitiators can be used to profile simple and complex chemical mixtures using an array of polymers with distinct binding properties. The OpsisDx™ research team is exploring whether this approach can can be the basis for a multi-disease detection platform that may

PCRopsis LLC launches Oral Rinse: a unique device for the collection and transportation of oral samples with distinct advantages

Oral samples offer a simple, low cost, and user-friendly means of collecting oral samples for a variety of applications; such as, DNA sequencing, respiratory virus testing, oral cancer detection, toxicology, and many others. These samples can be conveniently collected at home and shipped to testing sites.

Key Advantages of PCRopsis™ Oral Rinse over Alternative Approaches:

1. Simple sample collection: safe ingredients allow for self collection of oral samples by swishing the liquid in your mouth – no need for swabs, secondary inactivating reagents, careful mixing of saliva with reagents, or pipettes to transfer small volumes
2. Keeps RNA stable at room

Entopsis creates PCRopsis LLC as a separate entity

Entopsis Inc. has developed a wide range of technologies in the life sciences industry, such as OpsisDx, PCRopsis, PlantOpsis, ZooOpsis, and Genurine. Each set of technologies addresses a distinct market niche, with distinct clients, key opinion leaders, business and scientific expectations, regulatory landscape, and interested investors. As such, Entopsis will create subsidiaries for each set of technologies to best address the particular business needs of each product line. The subsidiaries will hold exclusive rights to the underlying technology, while Entopsis will perform common operational tasks.

PCRopsis™ RVD Enhancer makes PCRopsis™ Reagent RVD compatible with most specimen transport mediums

PCRopsis™ Reagent RVD + PCRopsis™ RVD Enhancer offers a direct PCR solution for specimens in most non-inactivating transport mediums.

PCRopsis™ Reagent RVD alone has been repeatedly shown to facilitate extraction-free amplification of viral, bacterial, and mammalian specimens in universal viral transport (UVT) mediums, like BD™ Universal Viral Transport system. This is one of the most common specimen transport mediums in the U.S., although many other transport mediums are used in the U.S. and abroad.

Entopsis developed PCRopsis™ RVD Enhancer to expand the compatibility of PCRopsis™ Reagent RVD to process specimens in diverse transport mediums. PCRopsis™ Reagent RVD, when used in

PCRopsis™ Reagent RVD was recently shown to mediate direct PCR amplification from viral and bacterial targets using low volumes of reagent and sample, thus drastically lowering costs and increasing testing accessibility.

Reagent RVD is a flexible direct PCR product for various research and clinical applications. The PCR testing industry is particularly price-conscious, with thin profit margins. As such, laboratories seek affordable and accurate solutions to offer clients the best services.

Recent miniaturization studies confirm Reagent RVD facilitates extraction-free RT-PCR and qPCR for less than $5 per reaction. Typically, RNA and DNA extraction kits cost $5.00 ~ $10.00 per extraction, when

The Entopsis Family Grows with the Launch of the Global Health Institute

Have you ever read about cool, new medical products / tests, only to later realize it won’t be available for years into the future (if ever)?

Entopsis is effectively a R&D company that creates novel, impactful technologies for the bio-medical space. They are best known for OpsisDx™ (single platform to diagnose diseases early through urine) and PCRopsis™ (clinical tools that make diagnostic tests more efficient). This team of hard-core scientists and engineers usually rather license technologies, than sell directly to consumers.

This is where the Global Health Institute (GHI) comes in. GHI’s mission is to de-risk new clinical technologies by

Reagent RVD has proven capable of amplifying SARS-CoV-2 gene targets directly from universal viral transport (UVT) medium without the need for viral RNA extraction. However, diagnostic reference laboratories also want to use this approach for the amplification of bacterial gene targets.

The PCRopsis™ research team has extended their validation efforts in this direction. It’s been confirmed that Reagent RVD is capable of mediating extraction-free qPCR of specimens containing gram positive and negative bacteria.

To date, Reagent RVD facilitates extraction-free amplification of viral, bacterial and human gene targets directly from UVT.

This opens the door to new applications with Reagent

Non-invasive OpsisDx Diagnostic Test Awarded US Academy of Medicine Research Global Award

The U.S. National Academy of Medicine’s Healthy Longevity Global Grand Challenge has awarded a grant to develop Entopsis’ OpsisDx(TM) platform for detecting Parkinson’s disease using skin swabs or urine. This effort is driven by Entopsis’ scientific and clinical collaborators at Singapore’s Temasek Life Sciences Laboratory (TLL) and National Neuroscience Institute (NNI).

Read more about it here:

https://www.einnews.com/pr_news/529273833/national-academy-of-medicine-selects-opsisdx-for-co-development-of-a-urine-based-diagnostic-for-parkinson-s-disease

Non-invasive OpsisDx Diagnostic Test Awarded US Academy Research Grant

Entopsis Partners with Madison Core Labs: PCRopsis Reagent RVD

Our team’s passion is to innovate and create powerful, unheard-of solutions to the world’s problems. We pride ourselves on our creativity and desire to make a meaningful difference, both socially and scientifically.

However, we can only achieve our global goals with the right partners that share our mission. Today’s press release (see below) highlights one such partner, Madison Core Labs.

Link to Press Release

Madison Core Laboratories Initiates New Innovation Effort to Better Serve Clients

August 13, 2020 09:05 AM Eastern Daylight Time

HUNTSVILLE, Ala.–(BUSINESS WIRE)–

Page1of3

The Enchilada

Unmasking the Future of Cancer Detection: 10 AI Startups Leading the Charge

OpsisDx highlighted in peer-reviewed journal